It has indeed been shown that the miR-150 target gene repertoire can highly differ between different hematopoietic malignancies, e.g., MYB, FLT3, CBL and EGR2 in MLL-rearranged AML cells [25,26], and DKC1 and AKT2 in NK/T-cell lymphoma [8]. The gene discussed is CBL; the disease is acute myeloid leukemia.